Comedications with immune checkpoint inhibitors: involvement of the microbiota, impact on efficacy and practical implications

J Colard-Thomas, QD Thomas, M Viala - Cancers, 2023 - mdpi.com
Simple Summary Since the approval of immune checkpoint inhibitors for solid tumors,
concerns have been raised about the role of the microbiota on immunotherapy success and …

Immune Checkpoint Inhibitors and the Exposome: Host-Extrinsic Factors Determine Response, Survival, and Toxicity

EG Pizzutilo, R Romanò, L Roazzi, AG Agostara… - Cancer Research, 2023 - AACR
Cancer immunotherapy, largely represented by immune checkpoint inhibitors (ICI), has led
to substantial changes in preclinical cancer research and clinical oncology practice over the …

Novel evidence for the prognostic impact of β-blockers in solid cancer patients receiving immune checkpoint inhibitors

X Yan, P Liu, D Li, R Hu, M Tao, S Zhu, W Wu… - International …, 2022 - Elsevier
Objective Cancer immunotherapy based on immune checkpoint inhibitors (ICIs) has made
encouraging achievements in both clinical trials and real-world studies. The β-blockers, as …

Association between pretreatment emotional distress and immune checkpoint inhibitor response in non-small-cell lung cancer

Y Zeng, CH Hu, YZ Li, JS Zhou, SX Wang, MD Liu… - Nature Medicine, 2024 - nature.com
Emotional distress (ED), commonly characterized by symptoms of depression and/or
anxiety, is prevalent in patients with cancer. Preclinical studies suggest that ED can impair …

Beta-blocker exposure and survival outcomes in patients with advanced pancreatic ductal adenocarcinoma: a retrospective cohort study (BETAPANC)

A Le Bozec, M Brugel, Z Djerada, M Ayad… - Frontiers in …, 2023 - frontiersin.org
Introduction: Preclinical studies have demonstrated the possible role of beta-adrenergic
receptors in pancreatic ductal adenocarcinoma (PDAC) tumor invasion and migration. The …